Cocrystal Pharma, Inc. 8-K

What Happened
Cocrystal Pharma, Inc. (COCP) filed an 8-K reporting that the Board appointed James Sapirstein as Chief Executive Officer effective June 3, 2026. His employment offer provides an initial annual base salary of $265,000 and an annual performance bonus equal to 50% of base salary. Mr. Sapirstein replaces Sam Lee and James Martin as Co‑Chief Executive Officers; Mr. Lee remains President and Chief Scientific Officer and Mr. Martin remains Chief Financial Officer. The Offer Letter is filed as Exhibit 10.1.

Key Details

• Effective date: June 3, 2026; Mr. Sapirstein is age 64 and previously served as CEO of Entero Therapeutics (Oct 2019–Feb 2025) and as a consultant through Mar 2026.
• Initial equity: 10‑year stock options to purchase 235,000 shares, exercisable at $1.05 (closing price on grant date); vesting in four equal annual installments beginning June 3, 2027.
• Acceleration/termination terms: full vesting on a Change in Control; if terminated without Cause, 50% of unvested options accelerate.
• Potential additional grant: subject to continued employment, performance targets and Compensation Committee approval, options for an additional 235,000 shares may be granted on his six‑month anniversary (also vesting over four years).

Why It Matters
This filing signals a formal leadership change at Cocrystal with a single CEO replacing co‑CEOs while the prior co‑CEOs remain in senior roles, which may affect company strategy and execution. Compensation is weighted toward equity (options), aligning management incentives with shareholders but also representing potential future dilution — up to 470,000 option shares (235,000 initial + 235,000 potential) at an initial exercise price of $1.05. Investors should note the effective date, equity terms, and acceleration provisions disclosed in the Offer Letter.